No Data
Express News | U.S.-listed Chinese Stocks Rose in Overnight Trading
With 73% Ownership in Zai Lab Limited (NASDAQ:ZLAB), Institutional Investors Have a Lot Riding on the Business
ZAI LAB: NOTICE OF BOARD ACTION AND DATE OF PUBLICATION OF 2024 ANNUAL RESULTS ANNOUNCEMENT
Zai Lab Limited (NASDAQ:ZLAB): When Will It Breakeven?
Hong Kong stock movement | ZAI LAB (09688) rises over 8% as "Ripretinib" new indications are proposed for priority review.
ZAI LAB (09688) rose over 8%. As of the time of writing, it increased by 8.29%, reaching 22.85 HKD, with a transaction volume of 54.3165 million HKD.
Goldman Sachs released a deep investment value report on China's Biomedical sector, highlighting a bullish outlook on ZAI LAB (ZLAB.US/9688.HK) and four other companies.
Recently, Goldman Sachs released an in-depth investment value analysis report on China's biotechnology. Goldman Sachs believes that it remains Bullish on the biotechnology sector within China's Medical and Healthcare market, as China's innovation is gaining and will continue to gain Global recognition. A number of leading biotechnology companies are expected to achieve breakeven in 2025/2026. This profitability inflection point is of milestone significance for China's biotechnology industry. Goldman Sachs also stated that ZAI LAB (ZLAB.US/9688.HK), Legend Biotech, INNOCARE, BEIGENE, and INNOVENT BIO are preferred symbols, as these companies have all experienced core catalytic events this year.
